Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Adverse respiratory effects of opioids for chronic breathlessness: to what extent can we learn lessons from chronic pain?

Cornelia A. Verberkt, Marieke H.J. van den Beuken-van Everdingen, Jos M.G.A. Schols, Sushma Datla, Carmen D. Dirksen, Miriam J. Johnson, Sander M.J. van Kuijk, Emiel F.M. Wouters, Daisy J.A. Janssen
European Respiratory Journal 2018 52: 1800882; DOI: 10.1183/13993003.00882-2018
Cornelia A. Verberkt
1Dept of Health Services Research, Maastricht University, Maastricht, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cornelia A. Verberkt
  • For correspondence: c.vandenberg@maastrichtuniversity.nl
Marieke H.J. van den Beuken-van Everdingen
2Centre of Expertise for Palliative Care, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jos M.G.A. Schols
1Dept of Health Services Research, Maastricht University, Maastricht, the Netherlands
3Dept of Family Medicine, Maastricht University, Maastricht, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sushma Datla
4Hull York Medical School, University of Hull, Hull, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen D. Dirksen
5Dept of Clinical Epidemiology and Medical Technology Assessment, MUMC+, Maastricht, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam J. Johnson
4Hull York Medical School, University of Hull, Hull, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sander M.J. van Kuijk
5Dept of Clinical Epidemiology and Medical Technology Assessment, MUMC+, Maastricht, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emiel F.M. Wouters
6CIRO, Centre of Expertise for Chronic Organ Failure, Horn, the Netherlands
7Dept of Respiratory Medicine, MUMC+, Maastricht, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daisy J.A. Janssen
2Centre of Expertise for Palliative Care, Maastricht University Medical Centre (MUMC+), Maastricht, the Netherlands
6CIRO, Centre of Expertise for Chronic Organ Failure, Horn, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Chronic breathlessness: care must be taken not to generalise evidence on adverse effects of opioids from chronic pain inappropriately http://ow.ly/D7sR30kfskS

From the authors:

We would like to thank K.T.S. Pattinson and colleagues for their interest in our review and their comprehensive comments [1]. We agree that the quality of the included studies was low, and the studies were small and not designed to examine the safety of opioids, as stated in our discussion [2]. Indeed, respiratory depression was not included as an outcome in over half of the studies. Of note, in the 25 studies that did include the outcome, only 11 stated a definition. Therefore, we recommended in our review to include “a common respiratory outcome set in all trials of opioids for breathlessness, so that a more robust synthesis could be conducted”. Although chemoreflex response is useful in laboratory research, measurement of blood gases remains the basis for evaluation in clinical practice, with the assessment of arterial blood gases being more reliable than the assessment of capillary blood gases [3] or transcutaneous measurement [4].

K.T.S. Pattinson and colleagues suggest using knowledge from the world of analgesia for chronic noncancer pain. A systematic review published in 2015 [5] concluded that for some harms, including dependence, “higher opioid doses are associated with increased risk”. Therefore, it is questionable whether this knowledge can be extrapolated to the treatment of chronic breathlessness. The risk of tolerance to opioids used for analgesia has indeed been shown in patients on methadone maintenance therapy, using methadone doses of 50 mg (equivalent to 480 mg morphine) per day or more [6, 7]. With analgesia, high doses and dose escalation titrating against severity of pain are usual practice, but patients with breathlessness are treated with low-dose opioids (≤30 mg oral morphine equivalents a day [8]). Responders in a long-term effectiveness study (mean of 209.5 patient-days per participant) used a mean of 14 mg per day, of which only 7.7% used the highest dose of 30 mg per day to gain benefit [8]. In participants needing a dose increment up to 30 mg per day to gain benefit, improvement continued without further dose titration over the following 7 days, a phenomenon not described in pain response [9].

At the population level, Ekström et al. [10] showed that dosages <30 mg oral morphine equivalents a day were not associated with increased risk of hospitalisation or death among patients with chronic obstructive pulmonary disease (COPD) using long-term oxygen therapy over a 4-year follow-up. The excess 30-day mortality seen in the large observational cohort study we discussed in our review was statistically significant but very small; other factors might explain these findings and it is likely that the overwhelming majority were prescribed opioids for pain and not breathlessness [11].

For the effect of opioid therapy on breathing during sleep, a dose–response relationship was shown with the apnoea–hypopnoea index, with the majority of patients receiving high-dose opioids [12, 13]. It is not known if this conclusion can be drawn for low-dose opioids as well [14]. A recent overview of Cochrane reviews of opioid therapy for chronic pain found no case of respiratory depression, sleep apnoea or sleep-disordered breathing [15]. Nevertheless, while this Cochrane review did not focus on patients with COPD, we agree that measurement of overnight oximetry is needed to assess adverse effects of opioids for breathlessness and therefore we included pulse oximetry in the MORDYC study [16], for which we are currently collecting data.

Breathlessness is an extensive problem, experienced by many patients with chronic conditions [17, 18], and affects the quality of life of both patients and their caregivers [19]. Low-dose opioids are an effective treatment for chronic breathlessness, without a reported increase in hospital admissions or mortality [8, 10, 20]. The American Thoracic Society statement on dyspnoea concludes that “clinically significant respiratory depression is uncommon with the doses used to treat dyspnea” [21]. This is confirmed by our review, in which only five out of 1064 patients who were examined for respiratory depression experienced an episode reported as respiratory depression. Only one of these cases required ventilator support and occurred in a patient treated with high-dose morphine [22]. However, since the effects of opioid treatment for chronic breathlessness have never been examined in a long-term and well-powered randomised controlled trial, the MORDYC study [16] and BEAMS study [23] are being conducted. The MORDYC study primarily focuses on the effect of slow-release morphine on respiratory outcomes. The results of both studies should give more insight in the long-term effects and the harms of opioid therapy in low doses.

We agree that lessons learnt in the field of chronic noncancer pain must be heeded but care must be taken not to generalise inappropriately. As Pattinson [24] stated in a previous review regarding opioids as analgesia, “medical fear of respiratory depression means that pain is often undertreated and patients experience unnecessary suffering”. A balanced and meticulous approach is needed to guide future research and clinical practice to ensure safe use of this effective intervention for chronic breathlessness.

Footnotes

  • Support statement: The study to which this correspondence refers was supported by ZonMW grant 836031012. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Conflict of interest: C.A. Verberkt reports receiving grants from ZonMW, the Hague, during the conduct of the study.

  • Conflict of interest: M.J. Johnson's institution has received payment from Mayne Pharma for clinical consultancy, during the conduct of the study.

  • Conflict of interest: E.F.M. Wouters has received personal fees for board membership from Nycomed and Boehringer, grants from AstraZeneca and GSK, and payments for lectures from AstraZeneca, GSK, Novartis and Chiesi.

  • Conflict of interest: D.J.A. Janssen reports receiving grants from ZonMw, the Hague, during the conduct of the study; lecture fees from Boehringer Ingelheim, GSK, AstraZeneca, Almirall and Chiesi, and a consultancy fee from MaynePharma, outside the submitted work.

  • Conflict of interest: M.H.J. van den Beuken-van Everdingen reports grants from ZonMw, during the conduct of the study.

  • Received May 11, 2018.
  • Accepted May 20, 2018.
  • Copyright ©ERS 2018

References

  1. ↵
    1. Pattinson KTS,
    2. Rowland MJ,
    3. Nickol AH, et al.
    Adverse respiratory effects of opioids for chronic breathlessness: learning lessons from chronic pain. Eur Respir J 2018; 51: 1702531.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Verberkt CA,
    2. van den Beuken-van Everdingen MHJ,
    3. Schols J, et al.
    Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis. Eur Respir J 2017; 50: 1701153.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Higgins C
    . Capillary blood gases: to arterialize or not. MLO Med Lab Obs 2008; 40: 44–47.
    OpenUrlPubMed
  4. ↵
    1. Pauwels RA,
    2. Buist AS,
    3. Calverley PM, et al.
    Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256–1276.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Chou R,
    2. Turner JA,
    3. Devine EB, et al.
    The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162: 276–286.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Teichtahl H,
    2. Wang D,
    3. Cunnington D, et al.
    Ventilatory responses to hypoxia and hypercapnia in stable methadone maintenance treatment patients. Chest 2005; 128: 1339–1347.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Khoubnasabjafari M,
    2. Ansarin K,
    3. Jouyban-Gharamaleki V, et al.
    Methadone concentrations in exhaled breath condensate. Serum and urine of patients under maintenance treatment. Iran J Pharm Res 2017; 16: 1621–1630.
    OpenUrl
  8. ↵
    1. Currow DC,
    2. McDonald C,
    3. Oaten S, et al.
    Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage 2011; 42: 388–399.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Currow DC,
    2. Quinn S,
    3. Greene A, et al.
    The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea. J Palliat Med 2013; 16: 881–886.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Ekstrom MP,
    2. Bornefalk-Hermansson A,
    3. Abernethy AP, et al.
    Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 2014; 348: g445.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Vozoris NT,
    2. Wang X,
    3. Fischer HD, et al.
    Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J 2016; 48: 683–693.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Webster LR,
    2. Choi Y,
    3. Desai H, et al.
    Sleep-disordered breathing and chronic opioid therapy. Pain Med 2008; 9: 425–432.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Rose AR,
    2. Catcheside PG,
    3. McEvoy RD, et al.
    Sleep disordered breathing and chronic respiratory failure in patients with chronic pain on long term opioid therapy. J Clin Sleep Med 2014; 10: 847–852.
    OpenUrl
  14. ↵
    1. Chowdhuri S,
    2. Javaheri S
    . Sleep disordered breathing caused by chronic opioid use: diverse manifestations and their management. Sleep Med Clin 2017; 12: 573–586.
    OpenUrl
  15. ↵
    1. Els C,
    2. Jackson TD,
    3. Kunyk D, et al.
    Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews. Cochrane Database Syst Rev 2017; 10: CD012509.
    OpenUrl
  16. ↵
    1. Verberkt CA,
    2. van den Beuken-van Everdingen MH,
    3. Franssen FM, et al.
    A randomized controlled trial on the benefits and respiratory adverse effects of morphine for refractory dyspnea in patients with COPD: protocol of the MORDYC study. Contemp Clin Trials 2016; 47: 228–234.
    OpenUrl
  17. ↵
    1. Thomas S,
    2. Bausewein C,
    3. Higginson I, et al.
    Breathlessness in cancer patients – implications, management and challenges. Eur J Oncol Nurs 2011; 15: 459–469.
    OpenUrlPubMed
  18. ↵
    1. Janssen DJ,
    2. Spruit MA,
    3. Wouters EF, et al.
    Daily symptom burden in end-stage chronic organ failure: a systematic review. Palliat Med 2008; 22: 938–948.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Johnson MJ,
    2. Yorke J,
    3. Hansen-Flaschen J, et al.
    Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. Eur Respir J 2017; 49: 1602277.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Ekström M,
    2. Bajwah S,
    3. Bland JM, et al.
    One evidence base; three stories: do opioids relieve chronic breathlessness? Thorax 2018; 73: 88–90.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Parshall MB,
    2. Schwartzstein RM,
    3. Adams L, et al.
    An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012; 185: 435–452.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Lang E,
    2. Jedeikin R
    . Acute respiratory depression as a complication of nebulised morphine. Can J Anaesth 1997; 45: 60–62.
    OpenUrl
  23. ↵
    1. Currow D,
    2. Watts GJ,
    3. Johnson M, et al.
    A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol. BMJ Open 2017; 7: e018100.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Pattinson KT
    . Opioids and the control of respiration. Br J Anaesth 2008; 100: 747–758.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 52 Issue 1 Table of Contents
European Respiratory Journal: 52 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adverse respiratory effects of opioids for chronic breathlessness: to what extent can we learn lessons from chronic pain?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Adverse respiratory effects of opioids for chronic breathlessness: to what extent can we learn lessons from chronic pain?
Cornelia A. Verberkt, Marieke H.J. van den Beuken-van Everdingen, Jos M.G.A. Schols, Sushma Datla, Carmen D. Dirksen, Miriam J. Johnson, Sander M.J. van Kuijk, Emiel F.M. Wouters, Daisy J.A. Janssen
European Respiratory Journal Jul 2018, 52 (1) 1800882; DOI: 10.1183/13993003.00882-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Adverse respiratory effects of opioids for chronic breathlessness: to what extent can we learn lessons from chronic pain?
Cornelia A. Verberkt, Marieke H.J. van den Beuken-van Everdingen, Jos M.G.A. Schols, Sushma Datla, Carmen D. Dirksen, Miriam J. Johnson, Sander M.J. van Kuijk, Emiel F.M. Wouters, Daisy J.A. Janssen
European Respiratory Journal Jul 2018, 52 (1) 1800882; DOI: 10.1183/13993003.00882-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Correspondence

  • Treatable traits in ILD: why not consider acute exacerbations?
  • Inclusion of lung health outcomes in TB treatment trials
  • Understanding confounding in Mendelian randomisation studies
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society